We aimed to assess the efficacy , safety , and effective treatment duration of grazoprevir ( an HCV NS@/@A protease inhibitor ) combined with elbasvir ( an HCV NS@A inhibitor ) with or without ribavirin in patients with HCV genotype @ infection with baseline characteristics of poor response .